Proparacaine Ophthalmic

American Genomics, LLC · FDA-approved active Small molecule

Proparacaine Ophthalmic is a Local anesthetic (ester) Small molecule drug developed by American Genomics, LLC. It is currently FDA-approved for Topical anesthesia for ophthalmic procedures and examinations, Corneal anesthesia for diagnostic procedures. Also known as: Proparacaine, proparacaine hydrochloride 0.5%.

Proparacaine is a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission in the eye.

Proparacaine is a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission in the eye. Used for Topical anesthesia for ophthalmic procedures and examinations, Corneal anesthesia for diagnostic procedures.

At a glance

Generic name	Proparacaine Ophthalmic
Also known as	Proparacaine, proparacaine hydrochloride 0.5%
Sponsor	American Genomics, LLC
Drug class	Local anesthetic (ester)
Target	Voltage-gated sodium channels
Modality	Small molecule
Therapeutic area	Ophthalmology
Phase	FDA-approved

Mechanism of action

Proparacaine reversibly inhibits sodium influx through nerve cell membranes, preventing depolarization and conduction of pain impulses. This topical anesthetic effect is localized to the ocular surface and anterior structures, providing rapid onset of anesthesia suitable for ophthalmic procedures and diagnostic examinations.

Approved indications

• Topical anesthesia for ophthalmic procedures and examinations
• Corneal anesthesia for diagnostic procedures

Common side effects

• Corneal epithelial toxicity with prolonged use
• Transient stinging or burning upon instillation
• Allergic conjunctivitis
• Mydriasis

Key clinical trials

• Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections (PHASE4)
• Efficacy of Nanodropper-mediated Topical Anesthetic (PHASE4)
• Neurosensory Abnormalities in SymptomAtic Ocular Surface Patients (NASA)
• Subthreshold Micropulse Laser Therapy (SML) in Retinitis Pigmentosa (NA)
• An Investigation of the Impact of Localized Topical Anesthesia of the Ocular Surface on End-of-day Contact Lens Discomfort (NA)
• Optic Nerve Head Structural Response to IOP Elevation in Patients With Keratoconus (NA)
• Base Curves of Bandage Contact Lenses and Their Effects on Post Trans-PRK Vision and Pain (NA)
• VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Proparacaine Ophthalmic CI brief — competitive landscape report
• Proparacaine Ophthalmic updates RSS · CI watch RSS
• American Genomics, LLC portfolio CI

Frequently asked questions about Proparacaine Ophthalmic

What is Proparacaine Ophthalmic?

Proparacaine Ophthalmic is a Local anesthetic (ester) drug developed by American Genomics, LLC, indicated for Topical anesthesia for ophthalmic procedures and examinations, Corneal anesthesia for diagnostic procedures.

How does Proparacaine Ophthalmic work?

Proparacaine is a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission in the eye.

What is Proparacaine Ophthalmic used for?

Proparacaine Ophthalmic is indicated for Topical anesthesia for ophthalmic procedures and examinations, Corneal anesthesia for diagnostic procedures.

Who makes Proparacaine Ophthalmic?

Proparacaine Ophthalmic is developed and marketed by American Genomics, LLC (see full American Genomics, LLC pipeline at /company/american-genomics-llc).

Is Proparacaine Ophthalmic also known as anything else?

Proparacaine Ophthalmic is also known as Proparacaine, proparacaine hydrochloride 0.5%.

What drug class is Proparacaine Ophthalmic in?

Proparacaine Ophthalmic belongs to the Local anesthetic (ester) class. See all Local anesthetic (ester) drugs at /class/local-anesthetic-ester.

What development phase is Proparacaine Ophthalmic in?

Proparacaine Ophthalmic is FDA-approved (marketed).

What are the side effects of Proparacaine Ophthalmic?

Common side effects of Proparacaine Ophthalmic include Corneal epithelial toxicity with prolonged use, Transient stinging or burning upon instillation, Allergic conjunctivitis, Mydriasis.

What does Proparacaine Ophthalmic target?

Proparacaine Ophthalmic targets Voltage-gated sodium channels and is a Local anesthetic (ester).

Related

• Drug class: All Local anesthetic (ester) drugs
• Target: All drugs targeting Voltage-gated sodium channels
• Manufacturer: American Genomics, LLC — full pipeline
• Therapeutic area: All drugs in Ophthalmology
• Indication: Drugs for Topical anesthesia for ophthalmic procedures and examinations
• Indication: Drugs for Corneal anesthesia for diagnostic procedures
• Also known as: Proparacaine, proparacaine hydrochloride 0.5%